1. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes
- Author
-
Zafar Rasheed, A Al Salloom, Uzma Zafar, Hani A. Al-Shobaili, Jalees Farhan, and A R Meki
- Subjects
Microbiology (medical) ,Adult ,Male ,endocrine system ,endocrine system diseases ,Adolescent ,Clinical Biochemistry ,Immunology ,Interleukin-1beta ,Vitiligo ,Inflammation ,medicine.disease_cause ,Microbiology ,Autoimmunity ,Pathogenesis ,Young Adult ,immune system diseases ,Diabetes mellitus ,Immunology and Allergy ,Medicine ,Humans ,Interleukin 6 ,Child ,Type 1 diabetes ,biology ,business.industry ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Biochemistry (medical) ,nutritional and metabolic diseases ,Interleukin ,Middle Aged ,medicine.disease ,Peptide Fragments ,Infectious Diseases ,Diabetes Mellitus, Type 1 ,biology.protein ,Female ,medicine.symptom ,Inflammation Mediators ,business ,Biomarkers - Abstract
Vitiligo is a pigmentation disorder of unknown aetiology, but it has been reported in association with other autoimmune diseases including type 1 diabetes mellitus (T1D). Vitiligo and T1D share a common theory of autoimmunity, but still an inflammatory link between them remains to be investigated. This study investigates the status and contribution of the inflammatory markers tumour necrosis factor-α (TNFα), interleukin (IL)-6 and IL-1 in patients with vitiligo, T1D and vitiligo-associated T1D (Vt-T1D). The data showed that sera from Vt-T1D patients (n = 21) had higher levels of TNFα, IL-6 and IL-1β compared with vitiligo patients (n = 39), T1D patients (n = 37) or controls (n = 42). Interestingly, serum levels of IL-6 were found to be significantly higher in Vt-T1D patients compared with the levels of TNFα and IL-1β. These data also showed that IL-6 was high in Vt patients as compared to the levels of TNFa and L-1β, whereas in T1D patients, IL-6 and TNFα were almost the same but were higher than IL-1β. In conclusion, this is the first study to show an inflammatory link between vitiligo and T1D. The data conclude that IL-6 plays an important role in the pathogenesis of Vt-T1D patients and is likely to gain favour as a therapeutic target in these patients.
- Published
- 2015